Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna Neuberg

Showing results (71-80 of 354) with videos related to

Pageof 36
Sort By:
Blood|November 15, 2008
Protein disulfide isomerases are antibody targets during immune-mediated tumor destructionCatia Fonseca, Robert Soiffer, Vincent Ho, et al.
Cancer Research|December 17, 2010
Active immunotherapy induces antibody responses that target tumor angiogenesisJonathan Schoenfeld, Masahisa Jinushi, Yukoh Nakazaki, et al.
American Journal of Hematology|April 4, 2017
NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classificationOlga K Weinberg, Christopher J Gibson, Traci M Blonquist, et al.
The Journal of Clinical Investigation|June 17, 2004
Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycinJing Chen, Nathan R Wall, Kerry Kocher, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|January 18, 2014
Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitutionJanice P Dutcher, Donna Neuberg, Michael B Atkins, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 26, 2014
An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer centerAudrea H Szabatura, Frank Cirrone, Christy Harris, et al.
Transactions of the American Clinical and Climatological Association|January 11, 2013
Sickle cell disease (SCD), iNKT cells, and regadenoson infusionDavid G Nathan, Joshua Field, Gene Lin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 19, 2007
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remissionJennifer R Brown, Yang Feng, John G Gribben, et al.
Haematologica|January 13, 2018
Association of mutations with morphological dysplasia in <i>de novo</i> acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalitiesOlga K Weinberg, Christopher J Gibson, Traci M Blonquist, et al.
Blood|May 17, 2015
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse modelFabienne McClanahan, John C Riches, Shaun Miller, et al.
Pageof 36

Showing results (71-80 of 354) with videos related to

Sort By:
Pageof 36
Blood|November 15, 2008
Protein disulfide isomerases are antibody targets during immune-mediated tumor destructionCatia Fonseca, Robert Soiffer, Vincent Ho, et al.
Cancer Research|December 17, 2010
Active immunotherapy induces antibody responses that target tumor angiogenesisJonathan Schoenfeld, Masahisa Jinushi, Yukoh Nakazaki, et al.
American Journal of Hematology|April 4, 2017
NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classificationOlga K Weinberg, Christopher J Gibson, Traci M Blonquist, et al.
The Journal of Clinical Investigation|June 17, 2004
Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycinJing Chen, Nathan R Wall, Kerry Kocher, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|January 18, 2014
Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitutionJanice P Dutcher, Donna Neuberg, Michael B Atkins, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|March 26, 2014
An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer centerAudrea H Szabatura, Frank Cirrone, Christy Harris, et al.
Transactions of the American Clinical and Climatological Association|January 11, 2013
Sickle cell disease (SCD), iNKT cells, and regadenoson infusionDavid G Nathan, Joshua Field, Gene Lin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 19, 2007
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remissionJennifer R Brown, Yang Feng, John G Gribben, et al.
Haematologica|January 13, 2018
Association of mutations with morphological dysplasia in <i>de novo</i> acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalitiesOlga K Weinberg, Christopher J Gibson, Traci M Blonquist, et al.
Blood|May 17, 2015
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse modelFabienne McClanahan, John C Riches, Shaun Miller, et al.
Pageof 36